niacinamide has been researched along with Endometrial Neoplasms in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma." | 1.46 | Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. ( Bergadà, L; Boyd, J; Chen, BJ; Dolcet, X; Encinas, M; Eritja, N; Gatius, S; Llobet-Navàs, D; Martí, MD; Matias-Guiu, X; Ponce, J; Reventós, J; Ribera, J; Rodríguez-Barrueco, R; Santacana, M; Vidal, A; Villanueva, A; Yeramian, A, 2017) |
| "We exposed a panel of 12 endometrial cancer cell lines to a PI3K/mTOR inhibitor (voxtalisib, SAR245409) and/or a MEK inhibitor (pimasertib)." | 1.42 | Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. ( Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Kuramoto, H; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Uehara, Y; Wada-Hiraike, O; Yano, T, 2015) |
| "Sorafenib treatment correlated with a downregulation of both FLICE-Inhibitory Protein (FLIP) and myeloid cell leukaemia-1 (Mcl-1), caused by a proteasomal degradation of both proteins." | 1.36 | The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. ( Dolcet, X; Domingo, M; Eritja, N; Gonzalez-Tallada, FJ; Llobet, D; Matias-Guiu, X; Pallares, J; Santacana, M; Sorolla, A; Yeramian, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, NK | 1 |
| Huang, SL | 1 |
| Chang, TC | 1 |
| Chao, CC | 1 |
| Inaba, K | 1 |
| Oda, K | 1 |
| Ikeda, Y | 1 |
| Sone, K | 1 |
| Miyasaka, A | 1 |
| Kashiyama, T | 1 |
| Fukuda, T | 1 |
| Uehara, Y | 1 |
| Arimoto, T | 1 |
| Kuramoto, H | 1 |
| Wada-Hiraike, O | 1 |
| Kawana, K | 1 |
| Yano, T | 1 |
| Osuga, Y | 1 |
| Fujii, T | 1 |
| Mirantes, C | 1 |
| Dosil, MA | 1 |
| Eritja, N | 3 |
| Felip, I | 1 |
| Gatius, S | 2 |
| Santacana, M | 3 |
| Matias-Guiu, X | 3 |
| Dolcet, X | 3 |
| Chen, BJ | 1 |
| Rodríguez-Barrueco, R | 1 |
| Vidal, A | 1 |
| Martí, MD | 1 |
| Ponce, J | 1 |
| Bergadà, L | 1 |
| Yeramian, A | 2 |
| Encinas, M | 1 |
| Ribera, J | 1 |
| Reventós, J | 1 |
| Boyd, J | 1 |
| Villanueva, A | 1 |
| Llobet-Navàs, D | 1 |
| Llobet, D | 1 |
| Pallares, J | 1 |
| Sorolla, A | 1 |
| Domingo, M | 1 |
| Gonzalez-Tallada, FJ | 1 |
5 other studies available for niacinamide and Endometrial Neoplasms
| Article | Year |
|---|---|
Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Endometrial Neoplasms; ets-Domain Protein Elk-1; | 2013 |
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synerg | 2015 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neo | 2016 |
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Disease Progression; Endometrial Neopla | 2017 |
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Be | 2010 |